Core Insights - Evofem Biosciences, Inc. is focused on women's sexual and reproductive health, with recent developments including the acquisition of SOLOSEC® and licensing of Phexxi® in the Middle East [2][3][4] Company Highlights - The company acquired global rights to SOLOSEC® (secnidazole) 2 g oral granules, a single-dose oral antibiotic for treating bacterial vaginosis and trichomoniasis [2][3] - Evofem licensed commercial rights to hormone-free Phexxi® contraceptive gel in the Middle East to Pharma 1 Drug Store [2] - A partnership with Hello Alpha was established to offer Phexxi as a hormone-free contraception solution, targeting women on GLP-1s and those seeking hormone-free birth control [2] Recent Developments - Evofem's first FDA-approved product, Phexxi®, is a hormone-free, on-demand contraceptive vaginal gel, available in boxes of 12 pre-filled applicators [3] - The company is working towards closing a merger agreement with Aditxt, Inc., with the transaction expected to finalize in the second half of 2024 [4]
Evofem Biosciences to Present at the OTCQB Venture Virtual Investor Conference on August 1st